AAC Accepts, published online ahead of print on 26 February 2007
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindegardh, N.
Right arrow Articles by White, N. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindegardh, N.
Right arrow Articles by White, N. J

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01534-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Importance of collection tube during clinical studies of oseltamivir

Niklas Lindegardh*, Geraint R. Davies, Tran Tinh Hien, Jeremy Farrar, Pratap Singhasivanon, Nicholas P J Day, and Nicholas J White

Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, UK; Wellcome Trust Centre for Clinical Tropical Medicine, University of Liverpool, UK; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

* To whom correspondence should be addressed. Email: niklas{at}tropmedres.ac.


arrow
Abstract

Ex vivo conversion of the anti-influenza drug oseltamivir to its active metabolite can be inhibited by the esterase inhibitor dichlorvos or by using commercial fluoride/oxalate tubes. Oseltamivir and its active metabolite remain intact in plasma samples during a proposed virus heat inactivation step, incubation at 60°C for 45 minutes.




This article has been cited by other articles:

  • Wattanagoon, Y., Stepniewska, K., Lindegardh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., Singtoroj, T., Hanpithakpong, W., Davies, G., Tarning, J., Pongtavornpinyo, W., Fukuda, C., Singhasivanon, P., Day, N. P. J., White, N. J. (2009). Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 945-952 [Abstract] [Full Text]  
  • Holodniy, M., Penzak, S. R., Straight, T. M., Davey, R. T., Lee, K. K., Goetz, M. B., Raisch, D. W., Cunningham, F., Lin, E. T., Olivo, N., Deyton, L. R. (2008). Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid. Antimicrob. Agents Chemother. 52: 3013-3021 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»